{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:56:38Z","timestamp":1786460198824,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this scoping review is to identify, map, and characterize the evidence for assessments that measure driving performance in people taking benzodiazepine receptor agonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Benzodiazepines and Z-drugs are widely prescribed for the treatment of anxiety disorders and insomnia even though they are not recommended as an initial treatment for these indications. Benzodiazepine and Z-drug use is associated with an elevated risk of traffic accidents, and guidance documents instruct patients to consult with their health care providers for instructions on how to safely operate a motor vehicle while consuming these medications. However, little is known about the assessments that measure driving performance regarding the extent and length of impairment from the consumption of the individual benzodiazepines and Z-drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Inclusion criteria:<\/jats:title>\n                    <jats:p>Eligible studies will include participants who are new, intermittent, or chronic users of benzodiazepines and Z-drugs. No exclusions will be applied regarding the health status of participants or whether their benzodiazepine and Z-drug use is for an approved indication as indicated by government agencies (eg, Health Canada) or practice guidelines. Studies that examine the consumption of a benzodiazepine and Z-drug in association with the operation of a motor vehicle (real or simulated) with direct or indirect objective or standard subjective measures or indicators of impairment while operating a motor vehicle will be considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Embase (Elsevier), MEDLINE (Ovid), and PsycINFO (EBSCO) will be searched as sources of published studies. Only studies published in English will be included, and there will be no limit on dates of publication. After screening the titles and abstracts of identified citations, two independent reviewers will retrieve potentially relevant full-text studies and extract data. Data will be presented in diagrammatic or tabular form accompanied by a narrative summary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.11124\/jbisrir-d-19-00420","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T18:25:37Z","timestamp":1604600737000},"page":"242-250","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Driving performance assessments for benzodiazepine receptor agonist\u2013related impairment: a scoping review protocol"],"prefix":"10.11124","volume":"19","author":[{"given":"Andrea L.","family":"Murphy","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Dalhousie University, Halifax, NS, Canada"},{"name":"Aligning Health Needs and Evidence for Transformative Change (AH-NET-C): A JBI Centre of Excellence, Halifax, NS, Canada"},{"name":"College of Pharmacy, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie M.","family":"Peltekian","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Helwig","sequence":"additional","affiliation":[{"name":"Aligning Health Needs and Evidence for Transformative Change (AH-NET-C): A JBI Centre of Excellence, Halifax, NS, Canada"},{"name":"WK Kellogg Health Sciences Library, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Macdonald","sequence":"additional","affiliation":[{"name":"Aligning Health Needs and Evidence for Transformative Change (AH-NET-C): A JBI Centre of Excellence, Halifax, NS, Canada"},{"name":"School of Nursing, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Martin-Misener","sequence":"additional","affiliation":[{"name":"Aligning Health Needs and Evidence for Transformative Change (AH-NET-C): A JBI Centre of Excellence, Halifax, NS, Canada"},{"name":"School of Nursing, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandana","family":"Saini","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Neyedli","sequence":"additional","affiliation":[{"name":"School of Health and Human Performance, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Giacomantonio","sequence":"additional","affiliation":[{"name":"School of Nursing, Dalhousie University, Halifax, NS, Canada"},{"name":"Halifax Regional Police, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gardner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dalhousie University, Halifax, NS, Canada"},{"name":"College of Pharmacy, Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1]]},"reference":[{"issue":"(8)","key":"R1-20250613","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.sleep.2007.11.011","article-title":"Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam","volume":"9","author":"Gustavsen","year":"2008","journal-title":"Sleep Med"},{"issue":"(2)","key":"R3-20250613","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/M15-2175","article-title":"Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians","volume":"165","author":"Qaseem","year":"2016","journal-title":"Ann Intern Med"},{"issue":"(1)","key":"R4-20250613","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"(2\u20133)","key":"R5-20250613","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.healthpol.2010.03.008","article-title":"Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use","volume":"97","author":"Cunningham","year":"2010","journal-title":"Health Policy"},{"issue":"(7)","key":"R6-20250613","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.sleep.2011.12.014","article-title":"What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population","volume":"13","author":"Neutel","year":"2012","journal-title":"Sleep Med"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1478-7954-4-15","article-title":"Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians","volume":"4","author":"Kassam","year":"2006","journal-title":"Popul Health Metr"},{"issue":"(6)","key":"R8-20250613","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/jgs.15292","article-title":"Benzodiazepine use in older adults in the United States, Ontario, and Australia from 2010 to 2016","volume":"66","author":"Brett","year":"2018","journal-title":"J Am Geriatr Soc"},{"issue":"(4)","key":"R9-20250613","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.9778\/cmajo.20130076","article-title":"Use of benzodiazepines and related drugs in Manitoba: a population-based study","volume":"2","author":"Alessi-Severini","year":"2014","journal-title":"CMAJ Open"},{"issue":"(9)","key":"R10-20250613","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jamainternmed.2013.3795","article-title":"Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents","volume":"173","author":"Berry","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"(2)","key":"R11-20250613","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2125.2007.02861.x","article-title":"Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey","volume":"64","author":"Victorri-Vigneau","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"(2)","key":"R12-20250613","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3233\/JAD-151006","article-title":"Regular benzodiazepine and Z-substance use and risk of dementia: an analysis of German claims data","volume":"54","author":"Gomm","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"(11)","key":"R13-20250613","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/pds.4028","article-title":"The association between benzodiazepines and influenza-like illness-related pneumonia and mortality: a survival analysis using UK Primary Care data","volume":"25","author":"Nakafero","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"(2)","key":"R14-20250613","first-page":"163","article-title":"In the Zzz zone: the effects of Z-drugs on human performance and driving","volume":"9","author":"Gunja","year":"2013","journal-title":"J Med Toxicol Off J Am Coll Med Toxicol"},{"issue":"(S2)","key":"R17-20250613","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/(SICI)1099-1077(1998110)13:2+<S115::AID-HUP56>3.0.CO;2-O","article-title":"Benzodiazepine-related traffic accidents in young and elderly drivers","volume":"13","author":"Neutel","year":"1998","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"(3)","key":"R18-20250613","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FTD.0000000000000138","article-title":"Sedative-hypnotics are widely abused by drivers apprehended for driving under the influence of drugs","volume":"37","author":"Kriikku","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"(4)","key":"R26-20250613","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hup.2406","article-title":"Excursions out-of-lane versus standard deviation of lateral position as outcome measure of the on-the-road driving test","volume":"29","author":"Verster","year":"2014","journal-title":"Hum Psychopharmacol"},{"issue":"(3)","key":"R27-20250613","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/ijerph6031041","article-title":"Psychoactive medication and traffic safety","volume":"6","author":"Verster","year":"2009","journal-title":"Int J Environ Res Public Health"},{"issue":"(3)","key":"R28-20250613","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","article-title":"Guidance for conducting systematic scoping reviews","volume":"13","author":"Peters","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"R29-20250613","article-title":"Chapter 11: Scoping Reviews","author":"Peters","year":"2017","journal-title":"JBI Reviewer's Manual [Internet]"},{"issue":"(7)","key":"R30-20250613","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"(1)","key":"R31-20250613","first-page":"1000","article-title":"The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI)","volume":"17","author":"Munn","year":"2019","journal-title":"Int J Evid Based Healthc"}],"container-title":["JBI Evidence Synthesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.11124\/JBISRIR-D-19-00420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:35:04Z","timestamp":1786451704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.11124\/JBISRIR-D-19-00420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.11124\/jbisrir-d-19-00420","relation":{},"ISSN":["2689-8381"],"issn-type":[{"value":"2689-8381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}